Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of fuzuloparib + abiraterone + prednisone versus placebo + abiraterone + prednisone as first-line treatment for metastatic castration-resistant prostate cancer
CTR20202658Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Apr 2021; status: active.
02
Drugs
fluzoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20202658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202658.